<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749046</url>
  </required_header>
  <id_info>
    <org_study_id>11-MPP02EPI</org_study_id>
    <secondary_id>11-МРР02ЕРI</secondary_id>
    <nct_id>NCT01749046</nct_id>
  </id_info>
  <brief_title>Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures</brief_title>
  <official_title>Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose of Remegal as Adjunctive Therapy in Patients With Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valexfarm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valexfarm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is
      effictive and safe in patients with epilepsy with partial seizures
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure Frequency Reduction</measure>
    <time_frame>12 weeks</time_frame>
    <description>The assessment of efficacy will be based on the reduction of total partial seizure frequency reported in the patient's diary during the Treatment phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seizure's-Free Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number seizure's-free days during the Maintenance phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical Global Impression of change (CGI) at the end of Titration and Maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients' Global Impression of change (PGI) at the end of the Titration and Maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIE</measure>
    <time_frame>14 weeks</time_frame>
    <description>Assessment of Quality of Life Instrument in Epilepsy (QOLIE) at the Baseline Visit and at the end of Maintenance Phase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Epilepsy</condition>
  <condition>Simple Partial Seizures</condition>
  <condition>Complex Partial Seizures</condition>
  <condition>Partial Seizures With Secondary Generalization</condition>
  <arm_group>
    <arm_group_label>Remegal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remegal 1500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remegal</intervention_name>
    <description>Remegal 1500 mg for 12 weeks</description>
    <arm_group_label>Remegal</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Beprodon</other_name>
    <other_name>AED</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman, aged from 18 to 65

          -  Diagnosis of epilepsy with simple and/or complex partial seizures both with or without
             secondary generalization based on the ILAE classification

          -  Results of at least one prior electroencephalogram (EEG) and magnetic resonance
             imaging (MRI)/computerized tomography scan no more than 5 years should confirm the
             diagnostic of partial seizures

          -  If seizures are simple partial ones, only patients with motor signs must be enrolled

          -  The onset date of partial seizures according to patient's report must be at least 2
             years

          -  The patient must report an average of at least 8 partial seizures per 56 days prior to
             the baseline visit

          -  The patient must not have seizure-free period longer than 21 days during the 8 weeks
             prior to the baseline visit (i.e between V1 and V2)

          -  Patients must have been treated with at least 2 different AEDs within the last 2 years
             prior to the screening visit

          -  The patient is capable and would like to respect all protocol requirements, include to
             be available for the doctor's calls and doctor's appointments at any time, follow
             through all protocol procedures

          -  The patient agrees to self - report each seizure he has experienced between 2 visits,
             accurately and thoroughly, in a diary he'll be provided with

        Exclusion Criteria:

          -  Patients suffering from non-epileptic seizures

          -  Patients having seizures that can't be counted due to clustering.

          -  History of primary generalized seizures

          -  History of status epilepticus within 12 months prior to the screening visit

          -  The patient has received not permitted concomitant medications

          -  The patient has a progressive structural lesion in the CNS, or a progressive
             encephalopathy

          -  The patient is pregnant (or planning to become pregnant during the study) or is a
             lactating woman

          -  The patient has used Remegal previously or participated in a clinical study within 24
             weeks prior to the screening visit

          -  The patient has experienced of any somatic disorders or psychiatric diseases and
             conditions which, in the opinion of the investigator, lead to health worsening or
             influence on the patient ability to participate in the actual clinical study

          -  Vulnerable patients and individuals of majority age who are subject to legal
             protection or unable to express their consent

          -  The patient has a history of chronic alcohol consumption or drug abuse within 2 years
             prior to the screening visit

          -  The patient has a known history of a severe anaphylactic reaction or severe changes in
             blood tests

          -  ALT, AST, alkaline phosphatise, total bilirubin or serum creatinine level ≥ 2 times
             the upper limit of normal ranges

          -  Clinically important abnormalities on physical examination, vital signs, ECG or
             laboratory test results per-formed/obtained at the screening visit that may interfere
             with patient's safety, compliance, or study evaluations, ac-cording to the
             Investigator's opinion

          -  The patient has a clinically significant disease, surgical condition or recent chronic
             consumption of non-AED medications (within 4 weeks prior to the screening visit) that
             might be reasonably expected to interfere with drug absorption, distribution,
             metabolism, excretion

          -  QTc interval on the ECG performed at the screening visit above 500 ms

          -  Diseases or concomitant medications that may prolong QTc interval
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sverdlovsk region neuropsychiatric clinic</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Region psychiatric clinic</name>
      <address>
        <city>Kemerovo</city>
        <zip>650036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow regional psychiatric hospital</name>
      <address>
        <city>Moscow</city>
        <zip>127083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical University</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State psychiatric hospital №6</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>193167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical University</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican psychiatric dispensary</name>
      <address>
        <city>Saransk</city>
        <zip>430030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Academy</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical unit of disel equipment</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epileptic seizures, Partial seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

